四川海梦智森生物制药

Sichuan Haimeng Zhisen Biopharmaceutical is a China-based biotechnology company dedicated to the discovery and development of innovative small molecule drugs using targeted protein degradation (TPD) technology. The company leverages its proprietary PROTAC and molecular glue platforms to address high-unmet-need targets in oncology and immunology that were previously considered undruggable. Its lead candidate, HMZS-001, is an orally available PROTAC targeting the androgen receptor for the treatment of metastatic castration-resistant prostate cancer. Headquartered in the Chengdu Medical City, the firm is led by a team of experienced scientists with backgrounds in global pharmaceutical research. Haimeng Zhisen aims to provide next-generation therapies that overcome resistance to traditional small molecule inhibitors.